



# **Clinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents**

Reference: NHS England F03X08

## **FINAL VERSION FOR CONSULTATION**

*Information Reader Box (IRB) to be inserted on inside front cover for documents of 6 pages and over, with Publications Gateway reference number assigned after it has been cleared by the Publications Gateway Team. Publications Gateway guidance and the IRB can be found on the Intranet.*

Draft for public consultation

# Clinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents

First published: Month Year

Prepared by NHS England Specialised Services Clinical Reference Group for **CRG**

Published by NHS England, in electronic format only.

Draft for public consultation

# FINAL VERSION FOR CONSULTATION

## Contents

Contents .....	3
Equality statement .....	4
Plain language summary .....	4
1. Introduction .....	5
2. The proposed intervention and clinical indication.....	6
3. Definitions .....	6
4. Aim and objectives.....	7
5. Epidemiology and needs assessment.....	8
6. Evidence base .....	9
7. Proposed criteria for commissioning .....	11
8. Proposed patient pathway .....	12
9. Proposed governance arrangements .....	12
10. Proposed mechanism for funding .....	13
11. Proposed audit requirements.....	13
12. Documents which have informed this policy .....	13
13. Date of review.....	13

# FINAL VERSION FOR CONSULTATION

## **Equality statement**

NHS England has a duty to have regard to the need to reduce health inequalities in access to health services and health outcomes achieved as enshrined in the Health and Social Care Act 2012.

NHS England is committed to fulfilling this duty as to equality of access and to avoiding unlawful discrimination on the grounds of age, gender, disability (including learning disability), gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion or belief, gender or sexual orientation.

In carrying out its functions, NHS England will have due regard to the different needs of protected equality groups, in line with the Equality Act 2010. This document is compliant with the NHS Constitution and the Human Rights Act 1998. This applies to all activities for which NHS England is responsible, including policy development, review and implementation.

## **Plain language summary**

HIV treatment (antiretroviral therapy or ART) has transformed the outlook for people living with HIV. ART enables most HIV positive people to be able to live a normal life with a normal life expectancy.

As people age, some medical concerns become very important. These include heart, kidney and bone disease. Some HIV drugs have side effects that overlap complications of ageing.

Until a cure is found, ART is lifelong. This means that most people will take ART for decades. It is therefore essential to minimise long-term side effects while making sure ART is still effective.

An evidence review looked at the safety and efficacy of Tenofovir alafenamide (TAF) compared to tenofovir disoproxil fumarate (TDF). It also looked at drug pricing.

After reviewing evidence from research, the policy concludes two main things.

1. That TAF, when used as part of ART, is as effective as TDF-based treatment.
2. TAF appears to have a lower risk of kidney and bone side effects in the short term although long term data is not available.

# FINAL VERSION FOR CONSULTATION

## 1. Introduction

HIV treatment (antiretroviral therapy, ART) has improved greatly over the last two decades and standard of care now involves triple therapy, typically with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus one of the following: a ritonavir/cobicistat-boosted protease inhibitor (PI/r), a non nucleoside reverse transcriptase inhibitor (NNRTI) or an integrase inhibitor (INI) [2].

ART requires good adherence (perhaps >95%) to avoid drug resistance and once commenced should be continued lifelong. Development of new ARV medicines often focuses on improvements in tolerability, reductions in toxicity and drug to drug interactions.

Effectiveness of ART is measured by its ability to reduce viral load to undetectable levels on routine tests (usually to less than 50 copies/mL). In England in 2014, 95% of patients on treatment had a viral load of less than 200 copies/mL. [1]. Current standard treatment is therefore effective for very many people. New drug treatments therefore need to demonstrate clinical and cost effectiveness and improved safety profiles compared to current standard treatments.

Tenofovir alafenamide (TAF) received an EU licence for treatment in HIV-1 infected adults and adolescents in November 2015 as a component of the fixed dose combination (FDC) Genvoya® (cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide).

Two other TAF containing formulations are likely to be given EU regulatory approval based mainly on bioequivalence/bioavailability data within the EU in 2016: a two-drug pill with FDC with emtricitabine and an FDC with rilpivirine and emtricitabine. Currently TDF is available as a single drug product, as part of a dual formulation with emtricitabine (Truvada®), and in three FDCs: Atripla® (efavirenz, emtricitabine, TDF) Eviplera® (rilpivirine, emtricitabine, TDF) and Stribild® (cobicistat, elvitegravir, emtricitabine, TDF).

TAF is manufactured by Gilead Sciences who also manufacture all these coformulated drugs.

TAF was approved in the EU based on studies showing similar efficacy but an improved safety profile compared with TDF.

The manufacturer has offered TAF at a commercially confidential price. Assuming that TAF is provided at the same price or lower than that offered to NHS England and agreed with the Commercial Medicines Unit, the availability of TAF as a treatment option would potentially benefit patients who would otherwise be treated with TDF and for patients for whom TDF was previously contraindicated because of underlying renal or bone disease. It will also be of wider short-term benefit to the NHS in terms of commissioning for value programmes.

It is anticipated that when additional TAF containing fixed dose combination products receive regulatory approval and become available the evidence review and commissioning criteria for TAF will be updated.

## FINAL VERSION FOR CONSULTATION

HIV drugs are not currently reviewed by NICE to determine their clinical and cost effectiveness.

### 2. The proposed intervention and clinical indication

The use of tenofovir alafenamide as part of combination antiretroviral therapy for the treatment of HIV 1 in adults and adolescents infected with HIV-1 immunodeficiency virus-1 (HIV-1). Adolescents are defined as children 12 years of age, or older and with a body weight in excess of 35kg

### 3. Definitions

The key terms used in this policy and their definitions are:

**Antiretroviral therapy (ART):** This usually consists of a combination of 3 antiretroviral drugs. A backbone of 2 nucleoside reverse transcriptase inhibitors (NRTI) and a 3rd agent from one of the following classes of drugs: non-nucleoside reverse transcriptase inhibitors (NNRTI), ritonavir or cobicistat boosted protease inhibitors (PI/r) and integrase inhibitors (INI).

**Fixed dose combination (FDC):** Single tablets that combine a complete ART combination into one pill.

**NRTI backbone:** The two NRTIs that are the basis of a combination. Two backbones are currently recommended for first line therapy: abacavir plus lamivudine (alternative in current guidelines [2]; available as separate tablets or in a combination pill and TDF plus emtricitabine (preferred in current guidelines [2]; available as separate tablets or in a combination pill); Both of these backbones are available in some 'all in one' tablets combined with other drugs.

**Viral load:** HIV RNA levels in plasma are used to monitor response to ART. Patients on effective therapy sustain viral load <50 copies/ml (undetectable). Patients in whom who fail to achieve an undetectable viral load is not sustained or who experience a confirmed viral load rebound to above 50 copies/ml are deemed to be experiencing virological failure.

**First-line therapy:** The first combination that someone is prescribed. Efavirenz is a recommended first line 3rd agent, given in combination with either tenofovir and emtricitabine or lamivudine and abacavir, and for reasons of clinical effectiveness and cost is the preferred first line option. (see section 5)

**Second-line therapy:** The use of alternative 3rd agents where efavirenz cannot be used for reasons of potential or actual intolerance or transmitted HIV drug resistance. Alternative 3rd agents include: the NNRTI rilpivirine, the INIs raltegravir, elvitegravir/cobicistat and dolutegravir, and the PI/rs darunavir/ritonavir or cobicistat and atazanavir/ritonavir or cobicistat. Drug selection depends on side effects profile, tolerability, resistance profile, drug-drug interactions and cost.

**Intolerance: when** patients either (i) experience side effects, or (ii) have been assessed to be at high risk of side effects.

**Stable patients:** patients who have a sustained undetectable viral load on ART and who are not experiencing side effects.

## FINAL VERSION FOR CONSULTATION

### 4. Aim and objectives

This policy aims to identify the evidence and cost implications of routine commissioning of TAF containing products for treatment of HIV 1 in adults and adolescents.

The objectives are to enable access to TAF where its use is supported by clinical evidence and where it is demonstrated to represent good value.

This policy aims to identify those patients who would benefit from TAF. This includes people in whom TDF would be indicated as a component of ART, those who are currently taking a TDF-containing regimen who would benefit from switching and those for whom TDF would be contra-indicated.

Draft for public consultation



## FINAL VERSION FOR CONSULTATION

### 5. Epidemiology and needs assessment

The HIV epidemic continues to pose a public health risk in England. By the end of 2014, an estimated 103,700 (CI 97,500-112,700) people were living with HIV in the UK; of whom 17% (18,100) were undiagnosed and unaware of their infection [1]. Whilst HIV-1 remains a life-threatening disease, effective antiretroviral therapy (ART) means it can be managed as a chronic long term condition and treatment outcomes in the England are good and compare very favorably to other European countries. In 2014 there were 78,317 HIV positive patients attended HIV services in England (85,489 in the UK), of whom 70,641 (91%) were receiving ART [1]. Of those receiving ART 95% had sustained viral suppression. There continues to be just over 6000 patients newly diagnosed with HIV in the UK per year and thus the number of patients attending HIV services and requiring ART continues to rise, (approximate 5% increase from 2013 to 2014). In the UK in 2010, 57,867 patients were on ART, rising to 76,462 patients in 2014. Ensuring patients continue to receive good and effective care but at the same time ensuring best use of resources is of high importance.

British HIV Association Treatment guidelines for adults currently recommend the following first-line [2]:

- **NRTI backbone:** tenofovir disoproxil fumarate and emtricitabine is the preferred option. Abacavir and lamivudine when used with dolutegravir is a preferred option, otherwise is an alternative option.
- **Third drug:** preferred options are atazanavir/ritonavir, or darunavir /ritonavir, or raltegravir or elvitegravir/cobicistat or rilpivirine, or dolutegravir. An alternative option is efavirenz. At the time of writing efavirenz is the least expensive 3<sup>rd</sup> agent so despite its alternative standing in the BHIVA guidelines it is a preferred option in regional prescribing pathways.

These guidelines remain under regular review for any new outcome data, the expiry of patents for standard of care drugs and the availability of new drugs. Where new drugs become available they need to have similar or better efficacy and safety profiles than current ARVs and should either be cost comparative or contribute significantly to commissioning for value programmes.

Tenofovir is a safe and widely used ARV. Evidence shows the new compound offers some additional benefits in the short term in terms of reduced toxicity for particularly patient groups; in addition the proposed pricing structure will contribute substantially to commissioning for value programmes.

## FINAL VERSION FOR CONSULTATION

### 6. Evidence base

#### Background and mechanism of action

Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are both pro-drugs of tenofovir. TDF is already one of the most widely used HIV drugs, especially in combination with emtricitabine. Both TAF and TDF need to be converted inside cells to the active version of tenofovir (tenofovir diphosphate). The difference between the two pro-drugs is that TDF is converted to tenofovir in the plasma which then enters cells to undergo the activation step; TAF, however, mainly enters cells in the TAF form and is then broken down to tenofovir followed by conversion to the active form. TAF results in similar active levels in cells but with much lower plasma concentrations of tenofovir, thought to be the main predictor of tenofovir-associated toxicity. Renal impairment and reduced bone mineral density are the most important reported tenofovir toxicities and TAF, by virtue of the lower plasma tenofovir levels, is associated with lower rates of abnormal markers (serum creatinine, estimated GFR, markers of proteinuria) for both side effects compared with TDF. TAF-based regimens are at least as effective as TDF-based treatments for first-line treatment and for treatment switch. TAF is associated with a less favourable lipids profile than TDF with greater rises in total-, LDL- and HDL-cholesterol; numerical differences are, however, small and when compared as Cobicistat, elvitegravir, emtricitabine, TDF vs elvitegravir/cobicistat/emtricitabine/TAF the average total:HDL-cholesterol ratio is the same for both. A summary of the trials investigating TAF-based HIV treatment follows:

#### Studies of TAF vs TDF in FDCs with elvitegravir/cobicistat/emtricitabine

- GS-102 and GS-104 compared elvitegravir/cobicistat/emtricitabine/TDF FDC with elvitegravir/cobicistat/emtricitabine/TAF FDC for first-line HIV treatment. In terms of efficacy, the TAF-based regimen was non-inferior to TDF-based treatment at 48 weeks. [3] There were low rates of resistance in both arms. The TAF-based group had significantly reduced impact on a range of biomarkers for renal and bone toxicity. Results at 96 weeks were similar [4]. Both FDCs are effective across a range of baseline viral loads.
- In GS-109 patients who were suppressed on TDF-based combinations either continued treatment or switched to elvitegravir/cobicistat/emtricitabine/TAF FDC. Individuals switching treatment were as likely to maintain viral suppression (97% vs 93%) and experienced significant improvements in biomarkers for renal health. Bone mineral density at the spine and hip increased in the TAF group [5].
- In GS-112 patients on suppressive treatment were switched to elvitegravir/cobicistat/emtricitabine/TAF FDC. Most (92%) maintained viral suppression and there were significant improvement in proteinuria and bone mineral density [6].
- There are small studies which have investigated the efficacy, tolerability and safety of elvitegravir/cobicistat/emtricitabine/TAF FDC in adolescents [7] and HIV/hepatitis B co-infected individuals [8].

#### F/TAF (emtricitabine/TAF) studies and R/F/TAF (rilpivirine/ emtricitabine/TAF):

## FINAL VERSION FOR CONSULTATION

- Bioequivalence data has been presented demonstrating TAF bioequivalence for elvitegravir/cobicistat/emtricitabine/TAF FDC and R/F/TAF [9] and for elvitegravir/cobicistat/emtricitabine/TAF FDC and F/TAF [10].

In **summary**, elvitegravir/cobicistat/emtricitabine/TAF FDC is as effective and well-tolerated as elvitegravir/cobicistat/emtricitabine/TDF FDC for first-line treatment and for switch treatment, but with indications of less renal and bone toxicity. It is also a safe switch option for patients already on HIV treatment with renal impairment that leads to improvements in renal and bone markers, at least in the short term. Other TAF-based products, F/TAF and R/F/TAF have shown TAF bioequivalence compared with elvitegravir/cobicistat/emtricitabine/TAF FDC; bioequivalence data will form the basis for the applications for marketing authorisation for F/TAF and R/F/TAF.

# FINAL VERSION FOR CONSULTATION

## 7. Proposed criteria for commissioning

The FDC elvitegravir/cobicistat/emtricitabine/TAF will be commissioned in the following situations:

### 1. Patients unable to tolerate first-line\* therapy

- Patients who are unable to take efavirenz (as current first line in regional guidelines) due to toxicity, resistance, intolerance or adherence issues as agreed in the HIV specialist multidisciplinary team (MDT), or
- Patients who are unable to take first- or other second-line treatments due to toxicity, intolerance or adherence issues as agreed in the HIV specialist multidisciplinary team (MDT). This includes patients who have either not tolerated other first or second line regimens or who for reasons of potential tolerability, toxicity and adherence issues should not be prescribed first or other second line regimens.

### 2. Stable patients switching from alternative ART regimens

- Patients stable on elvitegravir/cobicistat/emtricitabine/TDF can switch to Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (TAF).
- Patients stable on other combinations can switch to Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (TAF) where this is cost-neutral or cost-saving and where it is clinically appropriate and safe to do so.
- For any patient switching stable therapy the rationale for switch must be explained to patient and clearly documented

### 3. Pricing

- As Long as TAF is provided at the same price or lower than offered to NHS England and agreed with the Commercial Medicines Unit.

### Exclusions

- Patients starting therapy for the first time who are able to tolerate efavirenz based regimens as an alternative to elvitegravir/cobicistat/emtricitabine/TAF.
- Patients with proven or suspected resistance to any of the component drugs in elvitegravir/cobicistat/emtricitabine/TAF.
- Patients who have not been referred to and discussed in the HIV specialist MDT meeting or where the decision about their treatment is not recorded. Patients already on Cobicistat, elvitegravir, emtricitabine, TDF will not need additional discussion to switch to Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (TAF).
- Use of elvitegravir/cobicistat/emtricitabine/TAF by providers who are not commissioned by NHS England to provide HIV care and treatment services.
- Any increase in the price of elvitegravir/cobicistat/emtricitabine/TAF would require a review of this policy, as would any reduction in price of alternative combinations.
- Patients for whom the drug is contra indicated or data for use in that patient sub group does not exist to support the prescribing eg: HIV/HBV co-infection at the time of writing; these exclusions will likely change as more data becomes available

### Future TAF-containing drugs

Two formulations containing TAF have been developed and are being considered by

## FINAL VERSION FOR CONSULTATION

the regulatory authorities for approval in 2016:

- 1) Dual NRTI formulation of TAF plus emtricitabine; and
- 2) FDC of TAF, rilpivirine and emtricitabine

The use of these products will be similar to the current TDF-containing standard treatments (TDF/emtricitabine and TDF/rilpivirine/emtricitabine) but will also include patients with significant underlying renal and bone disease in whom TDF was previously contraindicated or in whom TDF use has required additional monitoring and more frequent patient follow up. The evidence review commissioning criteria and assessment cost impact for TAF will be reviewed and updated following the licensing authorisation for these TAF products.

### 8. Proposed patient pathway

Commissioned HIV care and treatment providers who meet the service specification initiate and monitor HIV drug treatment. Prescription and monitoring of TAF containing fixed dose combination products is in line with the existing patient pathway.

### 9. Proposed governance arrangements

All patients identified who might benefit from starting TAF as a part of the fixed dose combination product Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (TAF) for first or second line ART will in most cases be referred to and discussed at a specialist HIV MDT and the recommendation recorded. (see section 7)

All patients identified who are currently on TDF as part of Cobicistat, elvitegravir, emtricitabine, TDF and who might benefit from switching to TAF as part of Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (TAF) fixed dose product should be managed by regional/locally agreed best practice guidance for switching ARVs.

Patients deemed suitable for switch following medical review, this, must be undertaken with a planned approach to ensure no drug wastage occurs.

Once the fixed dose combination products containing TAF and emtricitabine or rilpivirine, emtricitabine and TAF receive regulatory authority approval it is anticipated that all patients who might benefit from taking TAF as part of these products should be managed by regional/locally agreed best practice guidelines and algorithms for starting first line therapy or switching therapy and may also require review and approval in a HIV MDT meeting. (see HIV CRG guidance for MDT meetings, February 2016).

This includes the cohorts identified for routine commissioning as well as any exceptional cases.

## FINAL VERSION FOR CONSULTATION

### 10. Proposed mechanism for funding

NHS England is responsible for funding the use of all antiretroviral medicines. Funding for ART is currently on a pass through basis reported to Commissioning Hubs.

### 11. Proposed audit requirements

1. Patients on Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (TAF) referred to MDT
2. Estimated GFR changes in patients commencing Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (TAF)
3. Hepatitis B outcomes in patients co-infected with HIV and hepatitis B who start or switch to elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (TAF)

### 12. Documents which have informed this policy

B06/S/a Specialised Human Immunodeficiency Virus (HIV) Services (Adult) – service specification

B06/S/b Specialised Human Immunodeficiency Virus (HIV) Services (Children) – service specification

### 13. Date of review

## FINAL VERSION FOR CONSULTATION

### References

- 1) Skingsley A, Kirwan P, Yin Z *et al.* HIV new diagnoses, treatment and care in the UK 2015 report: data to end 2014. October 2015. Public Health England, London.
- 2) Churchill D, Waters L, Ahmed N *et al.* BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. Accessed 5<sup>th</sup> February 2016 at <http://www.bhiva.org/documents/Guidelines/Treatment/2015/2015-treatment-guidelines.pdf>
- 3) Sax PE, Wohl D, Yin MT *et al.* Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. *Lancet* 2015; 385: 2606-15.
- 4) Wohl D, Oka S, Clumeck N *et al.* A Randomized, Double-Blind Comparison of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, for Initial HIV-1 Treatment: Week 96 results. EACS 2015; LBBPD1/1.
- 5) Mills A, Arribas JR, Andrade-Villaenueva J *et al.* Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. *Lancet ID* 2015; 16: 43-52.
- 6) Pozniak A, Arribas J, Gupta SK *et al.* Safety of tenofovir alafenamide in renal impairment. CROI 2015; P795.
- 7) Kizito H, Gaur A, Prasitsuebsal W *et al.* Safety, Efficacy and Pharmacokinetics of the Integrase Inhibitor-Based E/C/F/TAF Single-Tablet Regimen in Treatment-Naïve HIV-Infected Adolescents Through 24 Weeks of Treatment. CROI 2015; P953.
- 8) Gallant J, Brunetta J, Crofoot G *et al.* Efficacy and Safety of Switching to Simpler Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) in HIV-1/Hepatitis B Coinfected Adults in North America and Japan (NCT02071082): Week 48 Results. IAS 2015; WELBPE13.
- 9) Zack J, Doyle E, Graham H *et al.* Bioequivalence of a Fixed-Dose Combination of Rilpivirine/Emtricitabine/Tenofovir Alafenamide to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Rilpivirine. EACS 2015 PE10/6.
- 10) Zack J, Wst S, Rhee M *et al.* Bioequivalence of Two Dosage Strength Fixed-Dose Combination Formulations of Emtricitabine/Tenofovir Alafenamide (F/TAF) to Elvitegravir/Cobicistat/Emtricitabine/TAF (E/C/F/TAF) IAS 2015 TUBEB275.